Caribou Biosciences (CRBU) is discontinuing two cancer programs, cutting most staff, and launching a strategic review that could lead to a merger or sale. Shares dropped 36% after hours.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
